Connect Biopharma Holdings (CNTB) Accumulated Expenses (2023 - 2026)

Connect Biopharma Holdings (CNTB) has reported Accumulated Expenses for 4 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.

• Quarterly Accumulated Expenses rose 70.39% year-over-year to $12.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.3 million (up 70.39% YoY) and the FY2025 annual result came in at $11.2 million, up 43.04% from the prior year.
• Accumulated Expenses grew to $12.3 million in Q1 2026 per CNTB's latest filing, from $11.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for CNTB reached as high as $12.3 million in Q1 2026 and fell as low as $7.2 million in Q1 2025.
• A 4-year average of $9.3 million and a median of $8.9 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses retreated 17.69% — and 2026, when it jumped 70.39%.
• Year by year, Accumulated Expenses stood at $9.5 million in 2023, then retreated by 17.69% to $7.8 million in 2024, then surged by 43.04% to $11.2 million in 2025, then gained by 10.51% to $12.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $12.3 million, $11.2 million, and $8.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.